SCHEMBL6957529

SCHEMBL6957529

COc1ccc(COc2ncnc(N3CCc4ccccc4CC3)c2[N+](=O)[O-])cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.48
MGMT P16455 1/20 0.45
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.43
GPR119 Q8TDV5 7/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 1/20 0.41
CNR2 P34972 1/20 0.40
RAB9A P51151 2/20 0.40
AKT1 P31749 1/20 0.40
AKT2 P31751 1/20 0.40
AKT3 Q9Y243 1/20 0.40
KIT P10721 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KCNJ1 P48048 1/20 0.39
KCNH2 Q12809 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6949967 0.85 HTT (0.49) MGMTLMNAGPR119SMN1; SMN2HTT
SCHEMBL6957441 0.78 HRH4 (0.42) HRH4MGMTLMNATHRBSMN1; SMN2
SCHEMBL27631875 0.72 MGMT (0.42) MGMTLMNATHRBGPR119MAPT
SCHEMBL6948779 0.72 HTT (0.52) LMNASMN1; SMN2HTTMAPTMAPK1
SCHEMBL6947729 0.72 HTT (0.73) LMNASMN1; SMN2HTTRAB9AMAPT
SCHEMBL6949468 0.72 HTT (0.52) LMNASMN1; SMN2HTTRAB9AAKT2
SCHEMBL6949507 0.72 HTT (0.49) LMNAGPR119SMN1; SMN2HTTMAPT
SCHEMBL6951809 0.71 MEN1 (0.40) HRH4MGMTSMN1; SMN2HTTRAB9A
SCHEMBL6951855 0.70 ATM (0.43) GPR119SMN1; SMN2HTTMAPTMAPK1
SCHEMBL12733448 0.69 GPR119 (0.68) GPR119SMN1; SMN2RAB9AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed